Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $41.58 in the prior trading day, Exact Sciences Corp (NASDAQ: EXAS) closed at $43.10, up 3.66%. In other words, the price has increased by $3.66 from its previous closing price. On the day, 3.93 million shares were traded. EXAS stock price reached its highest trading level at $44.17 during the session, while it also had its lowest trading level at $40.8.
Ratios:
Our goal is to gain a better understanding of EXAS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.71 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 107.39. For the most recent quarter (mrq), Quick Ratio is recorded 1.92 and its Current Ratio is at 2.15. In the meantime, Its Debt-to-Equity ratio is 1.16 whereas as Long-Term Debt/Eq ratio is at 1.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $60.
On March 13, 2025, RBC Capital Mkts started tracking the stock assigning a Sector Perform rating and target price of $52.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $70.Barclays initiated its Overweight rating on January 23, 2025, with a $70 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 13 ’24 when Conroy Kevin T bought 19,500 shares for $51.35 per share. The transaction valued at 1,001,325 led to the insider holds 1,074,191 shares of the business.
Baranick Brian sold 929 shares of EXAS for $65,030 on Oct 08 ’24. The EVP, GM, Precision Oncology now owns 12,758 shares after completing the transaction at $70.00 per share. On Oct 08 ’24, another insider, Baranick Brian, who serves as the Officer of the company, bought 929 shares for $70.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 8006040576 and an Enterprise Value of 9743790080. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.90 while its Price-to-Book (P/B) ratio in mrq is 3.33. Its current Enterprise Value per Revenue stands at 3.532 whereas that against EBITDA is 327.401.
Stock Price History:
The Beta on a monthly basis for EXAS is 0.88, which has changed by -0.32158035 over the last 52 weeks, in comparison to a change of 0.017286062 over the same period for the S&P500. Over the past 52 weeks, EXAS has reached a high of $72.83, while it has fallen to a 52-week low of $39.97. The 50-Day Moving Average of the stock is -6.99%, while the 200-Day Moving Average is calculated to be -22.73%.
Shares Statistics:
The stock has traded on average 2.36M shares per day over the past 3-months and 3486810 shares per day over the last 10 days, according to various share statistics. A total of 185.62M shares are outstanding, with a floating share count of 182.94M. Insiders hold about 1.51% of the company’s shares, while institutions hold 99.47% stake in the company. Shares short for EXAS as of 1743379200 were 11167381 with a Short Ratio of 4.72, compared to 1740700800 on 10663382. Therefore, it implies a Short% of Shares Outstanding of 11167381 and a Short% of Float of 6.0700003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
